drugset / Trial / NCT02011464

Evaluation Exparel Delivered in Knee Replacement

NCT02011464 ↗

Phase 4 Completed 20 enrolled Maimonides Medical Center
RandomizedParallel-groupDouble-blindTreatment

Summary

Pain control after knee replacement requires analgesia to both the top (anterior) and bottom (posterior) portion of the the knee. Presently we use a nerve block for the anterior portion. The investigators want to to examine if giving Exparel into the posterior portion will give better pain relief. Hypothesis: There is no difference in, the use of analgesics or the length and quality of analgesia and no decrease in the time to be able to accomplish simple to complex knee movements using Exparel infiltration when compared to controls.

Timeline

Start
2013-12
Primary completion
2015-09
Completion
2015-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Bupivacaine Other / unclassified 20 ml Other